China Resources Pharmaceutical Group is a pharmaceutical and healthcare company engaged in the manufacturing, distribution, and retail of medical products. Its business segments include the industrial production of chemical drugs, traditional Chinese medicine, biological preparations, health products, and medical devices, alongside commercial distribution and retail pharmacy operations. Key subsidiaries include China Resources Pharmaceutical Commercial Group, China Resources Sanjiu, China Resources Shuanghe, China Resources Jiangzhong, Dong-E E-Jiao, and China Resources Boya Biopharmaceutical. The company serves therapeutic areas including cardiovascular, gastrointestinal, pediatric, respiratory, dermatology, blood products, and immunology. Its distribution network covers 28 provinces, autonomous regions, and municipalities in China. The retail segment operates a large pharmacy network, including DTP and dual-channel pharmacies. Notable brands include 999, Dong-E E-Jiao, Shuanghe, Jiangzhong, Boya, Zizhu, Kunzhongyao-1381, Tianshili, and Nanger.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - General Homepage crpharm.com
Sector Healthcare IR page crpharm.com
Tags
chemical drugs, traditional chinese medicine, biological preparations, medical devices, pharmaceutical distribution, retail pharmacy, blood products, health products, dtp pharmacy, China Resources Pharmaceutical Commercial Group, China Resources Sanjiu, China Resources Shuanghe, China Resources Jiangzhong, Dong-E E-Jiao, China Resources Boya Biopharmaceutical, China Resources Biopharmaceutical, Sichuan Nanger Biotechnology, China Pharmaceutical Research and Development Center, 999, Shuanghe, Jiangzhong, Boya, Zizhu, Kunzhongyao-1381, Tianshili, Nanger
Press page —

Metrics

Valuation  
Market cap HK$ 28.01B
Market cap (USD) $ 3.57B
P/E 6.21
PEG 1.65
P/BV 0.20
P/S 0.09
P/OCF 1.16
P/FCF 1.41
Dividend yield 5.4%
Turnover / mcap 0.06%
Returns  
ROE 3.8%
ROI 2.4%
ROIC 2.4%
Profit margin 1.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 3.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity 45.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 269.574B 257.673B 244.704B 221.802B 196.95B 178.872B 183.185B 164.569B 147.242B 134.668B 119.206B
Net profit 4.045B 3.351B 3.854B 3.62B 3.135B 2.943B 2.945B 3.503B 2.972B 2.425B 2.318B
Free cash flow 16.928B 14.333B 12.417B 7.054B — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price — 5.25 4.74 — — 4.06 — — — — —
Price performance 12m — 0.12 — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

China Resources Pharmaceutical GP Ltd (ticker 3320), listed in Hong Kong.

Company History

Date Change Detail
Dec 31, 2023 Reporting currency Its HK reports are in CNY instead of HKD from this period. Earlier figures are shown in CNY, converted at each period end's exchange rate.

ETFs Holding China Resources Pharmaceutical GP Ltd

ETF Weight in ETF Shares Market value As of
RFEM 0.23% 287,991 $ 178.103K Jul 31, 2026
AVEE 0.13% 292,500 $ 167.311K Nov 16, 2026
DFSE 0.03% 256,500 $ 146.321K Nov 12, 2026
DFEM 0.02% 2,735,500 $ 1.56M Nov 12, 2026
DFAE 0.01% 1,923,000 $ 1.097M Nov 12, 2026
AVEM 0.01% 4,682,500 $ 2.678M Nov 16, 2026
DFEV 0.01% 385,000 $ 219.624K Nov 12, 2026
DFAX 0.01% 1,424,500 $ 812.61K Nov 12, 2026